Sofosbuvir‐based treatment regimens: real life results of 14 409 chronic HCV genotype 4 patients in Egypt
Alimentary Pharmacology & Therapeutics2017Vol. 45(5), pp. 681–687
Citations Over TimeTop 10% of 2017 papers
A. Elsharkawy, Rabab Fouad, Wafaa Elakel, Maissa El Raziky, Mohamed Hassany, Gamal Shiha, Mohamed Said, Ibrahim Abdelghany Motawea, T. El Demerdash, Sameh Seif, Ahmed Gaballah, Yehia El Shazly, M. Makhlouf, Imam Waked, Ashraf Omar Abdelaziz, A. Yosry, Magdy El Serafy, Mark Thursz, Wahid Doss, Gamal Esmat
Abstract
Results of sofosbuvir-based therapies in Egypt achieved similar rates of SVR12 as seen in phase III efficacy studies.
Related Papers
- → Comparing the risk of hypothyroidism in HCV patients treated with different DAA drugs combinations (sofosbuvir + interferon + ribavirin and sofosbuvir + daclatasvir + ribavirin)(2020)5 cited
- → 751 Patient-Reported Outcomes in Chronic Hepatitis C Patients With Cirrhosis Treated With Ribavirin-Containing Regimens: Sofosbuvir/Velpatasvir and Ribavirin or Sofosbuvir and Ribavirin(2016)
- → TREATMENT OF CHRONIC HEPATITIS C GENOTYPE 6 PATIENT WITH TRIPLE THERAPY PEG-IFN, RIBAVIRIN AND SOFOSBUVIR: CASE REPORT AND REVIEW OF LITERATURE(2017)
- PE-074 : Efficacy and Safety of Sofosbuvir and Ribavirin in Treatment of HCV Genotype 2(2017)
- → Efficacy of Sofosbuvir Plus Ribavirin with and without Pegylated Interferon-Α in Patients with HCV Genotype 3A Infection(2021)